INTRODUCTION
In recent years a consensus on the use of TSH (thyroid stimulating hormone thyrotropln) as the primary test for the screening of thyroid disease has emerged. Yet on occasions, the inverse relationship between TSH and free thyroxine (FT4) or trliodothyronine (T3) may not hold, suggestive of pathology other than the thyroid or methodological artifacts. A sound understanding of physiology, biochemistry, and clinical issues related to thyrold function is a prerequisite to the proper Interpretation of results obtained with thyroid function tests. It is the purpose of this paper to provide an overview of variables affecting thyroid function and laboratory tests for screening and monitoring therapy.
PHYSIOLOGY AND BIOCHEMISTRY

Regulation of Thyroid function
of the anterior pituitary to produce TSH. The latter exerts Its effect on the thyroid gland through receptors on the thyroid cell to stimulate adenyt cyclase activity and Increase cyclic adenosine monophosphate (cAMP) level leading primarily to the synthesis of thyroid hormone, thyroxine or T 4. Many steps precede, under the influence of TSH, prior to the synthesis of T 4 by the thyroid gland. First the uptake of iodide by the thyroid gland is promoted by TSH. Iodide is oxidized to iodine by a peroxidase (thyroid peroxidase) enzyme. Iodine is added tothe tyrosine residues on the thyroglobulin molecule that is synthesized within the thyroid follicular cell. Two d~:Jotyrosines are coupled to form t etraiodot hyronine or T 4, which is cleaved from the thyroglobulin molecule by a proteolytic enzyme. Approximately 60% of T 4 circulates in the blood stream bound to thyroxine binding globulin (TBG), 30% bound to thyroxine binding prealbumin (TBPA) and 10% to albumin (TBA). Only 0.05% of T 4 is free which is the active hormone.
The regulation of thyroid function begins with the secretion of thyroid-releasing hormone (TRH), a tripeptide, by the hypothalamus in the brain. TRH also called thyroliberin is transported in the blood stream to the pituitary gland. TRH stimulates the cells The thyroid gland actually secrets T~ and T~ in a ratio of 10:1, Since T 4 is relatively inactive most of it is converted peripherally by monodeiodination to the active hormone T 3 (1) . There are two types of enzymes that affect monodeiodination, the majority of circulating T 3 is derived from the liver through the action of type 1 iodothyronine monodeiodinases (MDI) also called 51-deiodinase. The production of T 3 for local action in the brain, pituitary and brown adipose tissue is mediated by type II MDI. T 4 can either be sulfated or conjugated to glucuronic acid or deaminated to thyroacetic and thyropropionic acid derivatives. Among T 4 metabolites that are bioactive are T 3 and t riiodothyroacetic acid.
Role of T 3
T 3 interacts with nuclear receptors by binding to T~ regulatory regions of genes (thyroid hormoneresponse elements) and by modifying their expression, exerts thyroid hormone effects on target tissues (2). Thus T 3 increases the contractility of heart muscle by inducing the synthesis of myosin heavy chains. Tz increases low density lipoprotein (LDL) cholesterol receptors facilitating the cellular uptake of LDL and the lowering of serum cholesterol levels. T 3 also stimulates the transcription of the genes controlling the synthesis of sodium-potassium-ATPase in kidney, liver, skeletal, cardiac and adipose tissue leading to thermogenesis in these tissues (3). Free T 3 feeds back to the hypothalamus and the pituitary gland and thus regulates thyroid hormone levels. Hence when the hypothalamus-pitultary-thyroid axis is intact, a decrease in free T 4 or free T 3 leads to an increase in TSH, as in hypothyroidism, while an increase in free T 4 or freeT 3 suppresses TSH, a phenomena seen in hyperthyroidism. 70% of T 3 circulates in the blood stream bound to TBG, while 30% is bound to albumin. 0.5% of T 3 is in the active free form. In placenta an enzyme called type III deiodinase converts T 4 to reverse T 3 by removing the iodine in the 5 position of the inner ring of the thyroxine molecule (4). Reverse T~ is biologically inactive. Reverse T 3 levels are also increased in liver disease.
95% of circulating thyroid hormone is T 4. Although only 5% of circulating thyroid hormone is T 3 it matches the potency of the 95% of the circulating T 4 in terms of metabolic activity. Hence while T 4 is a major thyroid hormone, T 3 is the more potent and the active form of the hormone.
AUTOIMMUNE THYROID DISEASE
Chronic Autoimmune Thyroiditis
Hashimoto described in 1912 the case of four Indian Journal of Clinical Biochemistry, 1997. 12 (I) , [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] women in whom the thyroid gland was enlarged and had undergone what appeared to be a transformation into lymphoid tissue or struma lymphomatosa. Hashimoto's disease is currently regarded as a form of chronic autoimmune thyroiditis (5) . Apoptosis or programmed cell death of thyroid cells has recently been proposed as the cause of hypothyroidism in Hashimoto's thyroiditis (6) The antibodies in chronic autoimmune t hyroidltis are presumably generated when the T-helper lymphocytes (CD4) recognizing thyroid antigens are activated. In turn B lymphocytes are directed to the thyroid gland, and stimulated to produce antibodies. In addition to the production of antibodies directed to thyroid peroxidase enzyme, antibodies to thyroglobulin and thyrotropin (-I-SH) receptor have been characterized. Although the immune response resulting in the channeling of the cytotoxic lymphocytes (CD8) by activated CD4 cells into the thyroid gland is believed to be the main mechanism for the destruction of thyroid cells, thyroid autoantibodies may also have a role in the process that leads to hypothyroidism (5) . Thus for instance, the anti-thyrotropin (TSH)-receptor antibodies by blocldng the action of TSH can cause hypothyroidism.
Graves' Disease
Stimulating anti-thyrotropin-receptor antibodies by combining with the TSH receptor on the thyroid cell can mimic the action of TSH and cause hyppthyroidism as in Graves' disease, with patients presenting with characteristic ocular changes (ophthalmopathy).
Occasionally, hypothyroid patients with chronic autoimmune thyroiditis may go on to develop Graves' disease while hyperthyroid patients with Graves' disease, who are restored to normal by treatment may become hypothyroid after 10 or 15 years (5,7).
Predisposing Factors for Autoimmune Thyroid Disease
Predisposing factors for thyroid autoimmune disease are genetic and other augumenting exogenous factors such as an increased intake of iodine, treatment with iodine containing drugs such as amiodarone which has an iodine content of 35% by weight and long half-life, or therapy with lithium (5,
8,9).
Prevalence of Autoimmune Thyroid Disease
The prevalence of autoimmune thyroid disease increases with age with women likely to be more affected than men (5, 10) .
Very rarely patients with chronic autoimmune thyroiditis can develop thyroid lymphoma, the prevalence of which was reported to be higher in Japanese women (5, 11) .
Pregnancy and Ch ronic Autoimmu ne Thyroiditis
Among pregnant women with chronic autoimmune thyroiditis, the transfer of thyrotropin-receptorblocking antibodies through the placenta to the fetus can result in a small proportion of infants (about 5%) developing transient neonatal hypothyroidism (5, 12) .
Pregnant mothers with chronic autoimmune thyroiditis commonly go on to develop within two to six months after delivery, postpartum thyroiditis which is characterized by either hyper or hypothyroidism or a sequence of hyperthyroidism culminating in hypothyroidism. Postpartum thyroiditis is usually transitory with recovery effected in year's time frame (13) . However, a long term follow-up of patients with post partum thyroiditis revealed that a significant proportion of women who had recovered became hypothyroid after four years or longer (14) .
PATHOPHYSIOLOGY
TSH Secreting pituitary Adenomas
Inappropriate secretion of TSH has been noted in the face of hyperthyroidism, due to pituitary adenomas secreting TSH. More than 80% of TSHsecreting pituitary adenomas also cosecrete the free ~-subunit of TSH, the measurement of which could be helpful as a laboratory marker of this condition (15) .
Resistance to Thyroid Hormone
All tissues including the pituitary and peripheral organs become resistant to thyroid hormone. An abnormality in the T3-receptor-beta gene has been reported to be responsible for the syndrome of resistance to thyroid hormone which is usually characterized by an increase in serum levels of T 3 and T 4 with either normal or increased TSH and presenting with diffuse goiter and hypothyroidism (1, 16) . Greater than 20 mutations in the T3-receptor-beta gene have been identified, all of which are implicated in the reduction of the affinity of the receptor to T s (16) .
Effect of HCG
Human chorionic gonadotropin (HCG) has a weak thyrotropic activity. During normal pregnancy placental HCG is present at the highest concentration towards the end of the first trimester of pregnancy at which time serum TSH levels can be suppressed with a slight increase in free T 4 level (4). The increase in glomerular filtration rate in pregnancy leads to an increased clearance of iodide and there is a transfer of iodide and iodothyronines to the fetus. Hence the inorganic iodide level in serum decreases to the point that women with marginal iodine intake of less than 50 IJg/day develop iodine deficiency and, as a result, the enlargement of the thyroid gland. In the first trimester of pregnancy the clearance by liver of the sialylated thyroxine-binding globulin (TBG) which is induced by estrogens, is decreased. TBG level increases also due to the fact that estrogen stimulates its synthesis. Thus the increased level of total T 4 and T 3 in serum during pregnancy is due to the increase in TBG, their binding protein.
Effect of Trophoblastic and Ovarian Tumors
Tmphoblastic tumors produce modified HCG. Increase in the concentration of sialylated HCG, that have been reported in some trophoblastic tumors is the reason for the increased thyroid stimulator activity, since this fraction has a greater binding to the TSH receptor (17) .
In a ovarian tumor, characterized as struma ovarii, the tumor is composed of thyroid follicular tissue. This may cause hyperthyroidism with suppression of TSH (18) .
Subclinical Hypo and Hyper Thyroidism
Subclinical hypothyroidism is characterized by an increase in serum TSH, with either normal or decreased serum T 4, T 3, free thyroxine index (FT 4, an estimate of free T,=) and free T 3 levels. Hashirnoto's thyroiditis is presumed to be the most common cause accounting for 50% of the cases (19) . This condition also results after treatment of hyperthyroidism and use of iodine containing drugs such as amiodarone or therapy with lithium. Subclinical hyperthyroidism is characterized by decreased serum TSH level in the presence of normal serum total and free T 4 and T 3 level (19) . This condition is less frequent than subclinical hypothyroidism. This condition may result from treatment with an excessive dose of L-thyroxine.
Cardiac Abnormalities
Cardiac patients, especially over 60 years of age, whose only symptom is unexplained arrhythmia may have a decrease in serum TSH concentration. Such patients have a three-fold increased risk of developing atrial fibrillation over a 10-year period than elderly subjects with normal serum TSH (19, 20) .
The syndrome of apathetic hyperthyroidism refers to elderly patients in whom clinical hyperthyroidism is difficult to detect, since they have few of the symptoms and signs of disease. Measurement of TSH is helpful to rule out hyperthyroidism.
Non Thyroidal Illness
Alterations in thyroid function tests are seen in non thyroidal illness. Findings typically include decreased serum total and free T 3, decreased, normal or increased serum T 4, normal or decreased serum TSH, and increase in reverse T 3. Since this condition is transient, it is also called euthyroid sick syndrome. The condition may be related to the inhibition of 5' deiodinase (MDI) activity, decreased conversion ofT 4 to T 3 in peripheral tissues, decreased binding of TBG to T 4, and may also relate to the secretion of cytokines such as tumor necrosis factor c~ (TNF-s) by activated macrophages in many critical illnesses (21) . TNF-c~ has been reported to inhibit thyroid cell function in cultured thyroid cells. Biochemistry, 1997, 12 (I) , [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 
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LABORATORY EVALUATION
Thyrotropin (TSH) TSH is a glycoprotein which is synthesized by the beta cells of the anterior pituitary gland. Its molecular weight is 28 KD. It has an ~ and a beta subunit. The o~ subunit has homology to the ~ subunit of LH, FSH and HCG. As such, the antibody that is used to measure TSH is directed to the beta subunit.
TSH is currently accepted as the initial screening test for the assessment of thyroid function (22) . Laboratory tests for TSH have progressed from the first generation radioimmunoassay (RIA) with a functional sensitivity of 1-2 mU / L to the second generation immunometric assay with an improved sensitivity of 0.1-0.2 mU / L to the third generation ultrasensitive nonisotopic immunometric assays such as chemiluminometric assays with functional sensitivity improved to 0.01-0.02 mU / L. Indeed the fourth generation assays intended for research purposes can achieve a functional sensitivity of 0.001-0.002 mU / L (23). Incidentally, the functional assay sensitivity is defined as the lowest concentration of an analyte that can be measured with an interassay precision (coefficient of variation) or 20% or less.
Clinical Usefulness of TSH Measurements
TSH is the most sensitive test for the detection of subclinical hypo or hyperthyroidism. In subclinical hypothyroidism, TSH begins to increase long before a decrease in T 4 or free T 4 becomes apparent. Hence in evolving hypothyroidism one may have a normal T 4 and an above normal TSH. Indeed the relationship between TSH and free T 4 is log / linear with an approximately 100 or up to 160 fold change in TSH for a 1-fold change in free T 4. A suppressed TSH measured by a 3rd generation immunometric assay, when the free T 4 is still within the normal range is an indication of subclinical hyperthyroidism (19, 23) . This condition is normally seen when a hypothyroid patient is overtreated with L-thyroxine
(24).
The 3rd generation TSH assay is also helpful to distinguish hospitalized patients with nonthyroidal illness in whom TSH can be transiently depressed to levels in the 0.01-0.4 mUlL range from truly hyperthyroid patients in whom the TSH is suppressed below 0.02 mU / L (23).
The 3rd genereation TSH assay is also helpful in managing patients with thyroid cancer, especially in those with differentiated thyroid carcinoma where thetumors are TSH dependent, and, as such, receive a high dose of L-thyroxine therapy to suppress the trophic influence of TSH on thyroid tumor cells (23, 24) .
Caution in Interpreting TSH Results
It is important to note that there is a lag time before the pituitary gland responds to therapy. This is referred to as "pituitary lag". Thus it takes 6 to 8 weeks for the TSH to accurately reflect thyroid status after the initiation of therapy. During this period the free T 4 or its estimate (FT4index) is a sensitive indicator of recovery from either hypo or hyperthyroidism, with a precipitous rise or fall seen respectively in hypo or hyperthyroidism (23) .
We already noted that there is a transient suppression of TSH in nonthyroidal itlness, emphasizing the limitations of thyroid function tests in nonthyroidal illness.
As also noted earlier, TSH levels are suppressed towards the end of the first trimester of pregnancy, due to the weak thyrotropic activity of HCG whose level is highest towards the end of the first trimester of-pregnancy. In the 2nd and 3rd trimester of pregnancy TSH levels are more reliable making a case for trimester-based reference intervals for TSH in pregnancy.
Certain drugs such as prednisone can suppress TSH, while free T 4 remains within the normal range. TSH remains suppressed long after the normalization of free T 4 in patients who are undergoing therapy with propylthiouracil (25) .
Serum TSH levels are lowest around midday, with peak levels observed during the late evening hours (26) 
TSH Assay Format
Immunometric methods for TSH are non-competitive 2-site immunoassays which use an excess of antibody to TSH, which is normally monoclonal and is bound to a solid support. This antibody captures the TSH molecule in serum. At the same time a labeled mono or polyclonal antibody to TSH binds another epitope of TSH to form a sandwich. The label could either be radioactive, enzymatic, fluorometric or chemiluminescent. Subsequent to an incubation step varying from less than 30 minutes to 2 hours, the captured antibody-TSH-labeled antibody sandwich is washed and the amount of label bound is measured which is proportional to the concentration of TSH in serum (23) .
Interference with TSH Immunometric Assays
Murine (or mouse) monoclonal antibodies used in these assays are subject to interference by human anti-mouse or heterophile antibodies in the patient's serum. Binding of heterophile antibodies in human serum to murine antibodies used as reagents for capture and indicator antibody can mimic the presence of the desired analyte and cause its overestimation and hence a false positive result. The effect of the heterophile antibody will depend on the size of the immune complex that is formed when the reagent antibody combines with the heterophile antibody. Thus when heterophile antibodies in serum are in excess, there may even be underestimation of the desired analyte. Analyte binding by the indicator antibody can also be reduced by heterophile antibodies in which case the analyte is underestimated. Although assay kits are supplemented with non-specific mouse immunoglobulins to neutralize the heterophile antibodies, they may not always be sufficient to overcome the interference (26, 27, 28) .
Strategy for Thyroid Function Testing
Initially serum TSH level is determined by an immunometric assay. If it is within the normal range, thyroid function is presumed to be normal and no other test needs to be performed. If it is above 5.0 or 5.5 mU / L, hypothyroidism is suspected which is confirmed by free T 4 or free T 4 estimate (free thyroxine index or FT4). An assay for thyroid peroxidase antibody may be needed if Hashimoto's Thyroiditis is suspected. If TSH is below 0.4 or 0.3 mU / L, hyperthyroidism or non thyroidal illness is suspected. A free T 4 or free T 4 estimate is performed. If it is normal, T 3 assay is performed to establish the diagnosis. A 3rd generation TSH assay is needed if the TSH is less than 0.1 mU / L to distinguish true hyperthyroidism from non thyroidal illness (29, 30) .
When both TSH and T 4 and free T 4 are low, TRH stimulation test is used to distinguish between hypothalamic and pituitary dysfunction. The test involves injection of synthetic TRH after a base-line TSH measurement is performed. Thirty minutes later a blood sample is drawn and analyzed for TSH. If TSH levels increase, then the defect is in the hypothalamus. If it remains low, then the pituitary is defective.
Free T 4 Assays
The equilibrium dialysis or ultrafiltration technique, which are too involved for routine use, is, however, regarded as the gold standard for the measurement of free T 4.
Analogue methods for the measurement of free T 4 are competitive binding assays where theoretically free T 4 in serum competes with a labeled T 4 analogue for binding sites on the antibody to T 4. Thus the amount of labeled analogue that is measured is expected to be inversely proportional to the amount of free T 4 in the patient's serum. In reality there are biases associated with the analogue methods. The labeled T 4 analogue, which differs from T 4 in that the aianine side chain of the inner ring of T 4 is modified so that it does not bind to either TBG or TBPA, can still bind to albumin by the outer ring. Addition of blocking agents such as salicylic acid or 2,4-dinitrophenol to prevent the binding of labeled T 4 analogue to albumin, can sometimes result in the displacement of T 4 from TBG, leading to both a spuriously high free T 4 level when the TBG concentration is high and a low free T 4 level when the TBG concentration is low. Results obtained by analogue methods are dependent on the concentration of albumin and other binding proteins, and also on the concentration of free fatty acid which can bind to albumin and thus displace T 4 bound to albumin. In non thyroidal illness, the albumin and fatty acid leve',s can impact on the validity of free T 4 results. Because of these limitations, the analogue methods for the measurement of free T 4 have come under criticism
(31).
Methods using labeled antibodies for the measurement of free T 4 are also in use. Like the analogue methods, these methods also vary depending on the manufacturer's format, and the discrepancies among methods are related to the concentration of proteinbound T 4. At higher concentrations of protine-bound T 4, the discrepancies between methods are reduced, as compared to lower concentrations of protein-bound T 4, when larger variations between methods become apparent. The direct equilibrium dialysis reference procedure for free T 4 is not subject to the bias introduced by variations in the concentration of proteinbouncl T 4 (32).
Indirect Estimate of Free T4: The Free Thyroxine Index
The free thyroxine index (FT4) is estimated by the use of the total T 4 value and a value that estimates free binding sites on the TBG molecule. The later is estimated by a test called T 3 resin uptake. This test involves adding an excess of 1311-labeled T 3 to serum to saturate the free binding sites on the TBG molecule. A resin is added to bind to the free labeled T 3 that was not captured by the TBG molecule. A T 3 uptake ratio (T 3 U ratio) is computed by dividing the % resin T3U result obtained on the patient's sample by the % resin T3U from an euthyroid individual.
The FT 4 index is calculated by multiplying the T3U ratio by the total T 4 value obtained on the patient's serum.
The FT 4 index, although widely used for indirect estimation of free T 4 is also subjected to bias which is proportional to the concentration of protein-bound T, (33) .
Total T 4 and T 3 and Free T 3 Assays
The completeness of disassociation of T 4 and T 3 bound to their binding proteins and the inhibition of their reassociation is critical to the accuracy of their measurement. Bias related to the amount of serum T4-binding has been reported in the measurement of total "1"4 (34).
Analogue and labeled antibody immunoassay for free T 3 (FT3) have the same shortcomings as the corresponding methods for free T 4. The measurement of free T 3 after equilibrium dialysis, is accepted as a reference procedure (35) .
T 3 or T3 measurements may find application in patients with p'rtuitary disease or in those patients with suppressed pituitary function due to protracted hyperthyroidism (35) .
The ratio of serum FT 3 to FT 3 has been used in patients with Graves' disease to predict the outcome of anti-thyroid drug therapy, with ratio less than 55 predicting remission, and higher values indicating relapse (36) .
THYROID ANTIBODY ASSAYS Thyroid Peroxidase Antibodies (TPOAb)
Newer methods are based on the competition of coated monoclonal TPOAb with TPOAb in serum for added labeled peroxidase enzyme (TPO) is subsequently precipitated with protein A or captured on solid-phase protein A in the form of staphylococcus aureus cells. The diagnostic specificity and sensitivity of TPOAb measurements have been delineated (37) .
Thyroglobulin antibodies
Quantitative immunoassays based on ELISA and chemiluminescence are available for the measurement of thyroglobulin antibodies (TgAB) in serum. TgAb assessment adds little to the diagnostic value obtained from TPOAb measurements. However, when thyroglobulin levels are assayed it may be useful to ascertain the level of TgAb since the latter interferes in the measurement of thyroglobulin. In cases where TPOAb is negative, and thyroid autoimmunity is suspected TgAb assay can be helpful (37) .
TRAb measurements may be useful as a predictor of relapse of hyperthyroidism in Graves' disease. It may also be useful to ascertain the risk of fetal or neonatal thyrotoxicosis secondary to the transplacental passage of maternal TRAb especially in pregnant women with past or present Graves' disease ('37).
Drug Interferences in Thyroid Function Tests
A few examples of drug effects are cited here. Drugs. altering the level of binding proteins can affect the results. Thus estrogens, by increasing the synthesis of proteins can affect the results. Thus estrogens, by increasing the synthesis of TBG, increases total T,. Androgens by decreasing TBG decreases total T,. In both cases FT., levels are constant. Drugs such as salicylate, heparin and diazepam by competing for T, binding sites on albumin displace T,. Hence total T 4 is decreased. while FT, and T~ are increased. Drugs such as carbamazepine and phenytoin induce liver microsornal enzymes that alter clearance of T, leading to a decrease in total and FT 4 (26, 35) . Valproic acid inhibits liver microsomal enzymes. In addition to enzyme induction or inhibition, other mechanisms such as interference with the hypothalamic-pituitary response or induction of autoimmune reactions in the thyroid gland may be involved in the alteration of thyroid function tests by antiepileptic drugs (35) . Dopamine lowers TSH levels which normalizes promptly upon withdrawal of the drug (26) . Glucocorticoids such as dexamethasone can lower serum T 3 and basal TSH and stimulate release of TSH subsequent to TRH administration (26) .
Thyroid Receptor Antibodies (TRAb)
These antibodies could be either receptor stimulating or blocking antibodies. They can also be thyroid growth-stimulating, and thyrotropin binding inhibiting immunoglobulins (TBII). The routinely used methods are directed towards the measurement of thyroid-stimulating antibodies including TBII. A commercial procedure relies on TBII activity and is based on the percentage inhibition of ~l-labeled bovine TSH binqling to the TSH receptor preparation derived from human thyroid membranes (37) .
Unlike assays for TPOAb and TgAb for which medical research council calibrators are available, no such preparation for the standardization of TRAb has been developed. Biochemistry, 1997, 12 (1) , [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The effect of drugs such as amiodarone and lithium was referred to earlier in relation to predisposition to autoimmune disease. Amiodarone has a direct cytotoxic effect on thyroid gland, in addition to the iodine induced effect. As such, this drug can induce both hyper and hypothyroidism, amiodarone blocks the action of T3 at the level of the nucleus (1). Hypothyroidism may develop within 18 months after initiation of therapy, with patients having circulatory thyroid antibodies being 7 times more susceptible to this condition.
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Lithium induced hypothyroidism is often transient, and is more common in patients with thyroid antibodies. By the inhibition of the synthesis and release of T 4 from the thyroid gland lithium appears to decrease T 4 levels with an increase in TSH noted in 10 to 20% of treated patients (26) . It apparently does not affect the serum T 3 level (35) . Lithium can also cause hyperthyroidism. Drugs such as propranolol, and iodine containing contrast media inhibit T 4 to T 3 conversion, thereby increasing the serum total T 4 level, while lowering the concentration of serum T 3.
Excess iodine ingestion inhibits the uptake of iodide by the thyroid gland resulting in a decrease in both serum T 4 and T s levels.
CONCLUSION
The current availability of sensitive immunon~ric assays for TSH has made it ~ not only to accurately assess thyroid function but also to monitor the effectiveness of L-thyroxine replacement and suppression therapy. The importance of detecting congeni[al hypothyroid=sm in newborns, whose prevalence has been estimated to be 1 in 4000 births, and prompt treatment with L-thyroxine is critical to the prevention of serious mental and physical impairment in the child (24) .
Both excessive and undertreatment with L-thyroxir~e can be avoided by laboratory monitoring. Supp;ession of TSH secretion can produce symptoms simiiar to, but although less marked than in overt hyperthyroidism, such as an increase in the excretion of sodium in urine, increase in the activity of enzymes in the liver and muscle, a decrease in cholesterol levels, and an increase in the nocturnal heart rate to list a few (24) .
Likewise inadequate thyroxine replacement therapy can result in the presentation of characteristic clinical symptoms of hypothyroidism such as weakness, cold intolerance, weight gain, constipation, and skin color changes etc. Thus the laboratory has a special role in the diagnosis and monitoring of treatment of thyroid disorders. It also must be aware of the limitations of iaboratory tests. For instance serum thyrogiobulin measurements for the monitoring of thyroid cancer has both biological variabi[dy and analytical pitfalls which should be borne in mind when interpreting laboratory data (38) . In general, in addition to analytical variables, preanalytical variables, some of which were discussed earlier, should also be kept in perspective when interpreting thyroid function tests. Specimen collection variables, such as posture during blood sampling, the interaction of the blood specimen with the collection container, the effect of which may be dependent also on the assay format, and analyte stability should not be overlooked (26, 39) . Finally, the standardization of the various assay kits is critical to the attainment of performance goals set by expert iaboratodans (23) .
